Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class...